UBS Group
ADIL

UBS Group’s Adial Pharmaceuticals ADIL Stock Holding History

UBS Group’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49K Buy
19,147
+18,605
+3,433% +$36.9K ﹤0.01% 7577
2026
Q1 		$970 Buy
542
+175
+48% +$615 ﹤0.01% 9673
2025
Q4 		$2.02K Sell
367
-383
-51% -$3.1K ﹤0.01% 9404
2025
Q3 		$6.62K Buy
750
+254
+51% +$2.48K ﹤0.01% 8772
2025
Q2 		$3.74K Sell
496
-1,414
-74% -$21.4K ﹤0.01% 9324
2025
Q1 		$30.3K Buy
1,910
+1,069
+127% +$22.1K ﹤0.01% 7937
2024
Q4 		$21.2K Buy
841
+665
+378% +$17.3K ﹤0.01% 7829
2024
Q3 		$4.4K Sell
176
-3,168
-95% -$82.6K ﹤0.01% 8146
2024
Q2 		$96.1K Buy
3,344
+3,115
+1,360% +$118K ﹤0.01% 6184
2024
Q1 		$7.62K Buy
229
+84
+58% +$3.14K ﹤0.01% 7375
2023
Q4 		$6.74K Buy
145
+123
+559% +$6.74K ﹤0.01% 7675
2023
Q3 		$1.52K Buy
+22
New +$2.6K ﹤0.01% 7913
2023
Q2 		– Sell
-17
Closed -$3.72K – 8825
2023
Q1 		$3.72K Sell
17
-18
-51% -$4.36K ﹤0.01% 8284
2022
Q4 		$4.85K Sell
35
-22
-39% -$3.85K ﹤0.01% 9268
2022
Q3 		$12K Buy
+57
New +$25.7K ﹤0.01% 8136
2022
Q2 		– Sell
-11
Closed -$14K – 10241
2022
Q1 		$14K Buy
11
+5
+83% +$6.85K ﹤0.01% 7916
2021
Q4 		$10K Sell
6
-1
-14% -$1.97K ﹤0.01% 8754
2021
Q3 		$19K Buy
+7
New +$14.7K ﹤0.01% 7194
2021
Q2 		– Sell
-7
Closed -$11K – 9338
2021
Q1 		$11K Sell
7
-11
-61% -$16.6K ﹤0.01% 7843
2020
Q4 		$19K Buy
18
+16
+800% +$18.9K ﹤0.01% 6975
2020
Q3 		$3K Buy
+2
New +$1.86K ﹤0.01% 7504
2019
Q3 		– Sell
-3
Closed -$3K – 7950
2019
Q2 		$3K Sell
3
-3
-50% -$4.47K ﹤0.01% 7515
2019
Q1 		$13K Buy
6
+2
+50% +$5.96K ﹤0.01% 6626
2018
Q4 		$14K Buy
4
+3
+300% +$4.79K ﹤0.01% 7023
2018
Q3 		$2K Buy
+1
New +$2.08K ﹤0.01% 7722

Other funds holding ADIL

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCM
Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group's ADIL Position: Q2 2026 in Review

UBS Group increased its Adial Pharmaceuticals (ADIL) stake by 3,433% in Q2 2026, buying an estimated $36.9K and bringing the position to 19,147 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #7577.

UBS Group first reported a position in ADIL in Q3 2018 and has held it in 25 quarters since. The position peaked at $96.1K in Q2 2024. 17 funds tracked by Wall St. Rank hold ADIL as of Q2 2026.

  • UBS Group held 19,147 shares of Adial Pharmaceuticals worth $49K as of Q2 2026.
  • UBS Group bought 18,605 Adial Pharmaceuticals shares in Q2 2026, an estimated $36.9K.
  • Adial Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7577 holding.
  • UBS Group first reported a position in Adial Pharmaceuticals in Q3 2018 and has held it in 25 quarters since.
  • UBS Group's Adial Pharmaceuticals position peaked at $96.1K in Q2 2024.
  • 17 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.